Pressure Biosciences (PBIO) and Its Peers Critical Review

Pressure Biosciences (OTCMKTS: PBIO) is one of 25 public companies in the “Analytical instruments” industry, but how does it contrast to its peers? We will compare Pressure Biosciences to related companies based on the strength of its risk, earnings, institutional ownership, dividends, valuation, analyst recommendations and profitability.

Earnings and Valuation

This table compares Pressure Biosciences and its peers gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Pressure Biosciences $2.46 million -$9.70 million -0.16
Pressure Biosciences Competitors $1.14 billion $146.92 million 11.84

Pressure Biosciences’ peers have higher revenue and earnings than Pressure Biosciences. Pressure Biosciences is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Insider & Institutional Ownership

62.4% of shares of all “Analytical instruments” companies are owned by institutional investors. 15.9% of Pressure Biosciences shares are owned by insiders. Comparatively, 13.5% of shares of all “Analytical instruments” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Pressure Biosciences and its peers, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pressure Biosciences 0 0 0 0 N/A
Pressure Biosciences Competitors 183 917 1284 65 2.50

As a group, “Analytical instruments” companies have a potential upside of 0.70%. Given Pressure Biosciences’ peers higher possible upside, analysts clearly believe Pressure Biosciences has less favorable growth aspects than its peers.

Risk & Volatility

Pressure Biosciences has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500. Comparatively, Pressure Biosciences’ peers have a beta of 1.45, meaning that their average share price is 45% more volatile than the S&P 500.


This table compares Pressure Biosciences and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Pressure Biosciences -403.86% N/A -392.92%
Pressure Biosciences Competitors -212.02% -25.29% -11.33%


Pressure Biosciences peers beat Pressure Biosciences on 8 of the 10 factors compared.

About Pressure Biosciences

Pressure BioSciences, Inc. develops pressure cycling technology (PCT) solutions. Its PCT technology uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control the actions of molecules in biological samples, such as cells and tissues from human, animal, plant, and microbial sources. The company offers Barocycler instrumentations, including Barocycler 2320EXT, Barozyme-HT48, Barocycler NEP3229, HUB440, HUB880, and The Shredder SG3. It also distributes cell disruption equipment, parts, and consumables. In addition, the company offers Barocycler consumable products, such as PCT MicroTubes, PCT-MicroCaps, PCT-Micro-Pestle, PULSE Tubes, and BaroFlex 8-well Processing Strips, as well as application specific kits. Pressure BioSciences, Inc. serves researchers at academic laboratories; government agencies; and biotechnology, pharmaceutical, and other life sciences institutions in the United States, Europe, and Asia. Pressure BioSciences, Inc. has a collaboration with NutraFuels, Inc. for the development of water-soluble Nanoemulsion-based nutraceuticals. The company was formerly known as Boston Biomedica, Inc. Pressure BioSciences, Inc. was founded in 1978 and is based in South Easton, Massachusetts.

Receive News & Ratings for Pressure Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pressure Biosciences and related companies with's FREE daily email newsletter.